Metformin could serve as a potential adjunct therapy, as has been noted in EGFR mutant NSCLC patients receiving gefitinib plus metformin, versus gefitinib alone, in experimental gastric cancer models [34,166]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.